...
search icon
vtyx-img

Ventyx Biosciences Inc, Common Stock

VTYX

NSQ

$1.59

+$0.14

(9.66%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$85.39M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.69M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.73
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.78 L
$5.66 H
$1.59

About Ventyx Biosciences Inc, Common Stock

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameVTYXSectorS&P500
1-Week Return32.5%1.9%1.37%
1-Month Return40.71%1.36%15.76%
3-Month Return-4.22%-8.73%-2.58%
6-Month Return-7.56%-5.96%0.72%
1-Year Return-67.08%-7.97%12.24%
3-Year Return-91.38%3.54%52.73%
5-Year Return-92.44%34.17%100.37%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-30.00K470.00K941.00K-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":3.19,"profit":true},{"date":"2022-12-31","value":49.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit-(30.00K)(470.00K)(941.00K)-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-3000000,"profit":false},{"date":"2022-12-31","value":-47000000,"profit":false},{"date":"2023-12-31","value":-94100000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses7.05M67.15M113.14M207.99M148.45M[{"date":"2020-12-31","value":3.39,"profit":true},{"date":"2021-12-31","value":32.28,"profit":true},{"date":"2022-12-31","value":54.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":71.37,"profit":true}]
Operating Income(7.05M)(67.15M)(113.14M)(207.99M)(148.45M)[{"date":"2020-12-31","value":-705000000,"profit":false},{"date":"2021-12-31","value":-6714700000,"profit":false},{"date":"2022-12-31","value":-11313600000,"profit":false},{"date":"2023-12-31","value":-20799400000,"profit":false},{"date":"2024-12-31","value":-14845000000,"profit":false}]
Total Non-Operating Income/Expense(21.48M)(16.70M)9.38M29.67M26.74M[{"date":"2020-12-31","value":-72.4,"profit":false},{"date":"2021-12-31","value":-56.28,"profit":false},{"date":"2022-12-31","value":31.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":90.14,"profit":true}]
Pre-Tax Income(28.17M)(83.75M)(108.43M)(192.96M)(135.12M)[{"date":"2020-12-31","value":-2817400000,"profit":false},{"date":"2021-12-31","value":-8374600000,"profit":false},{"date":"2022-12-31","value":-10842600000,"profit":false},{"date":"2023-12-31","value":-19296200000,"profit":false},{"date":"2024-12-31","value":-13512200000,"profit":false}]
Income Taxes358.00K(5.38M)(470.00K)--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1502.79,"profit":false},{"date":"2022-12-31","value":-131.28,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(28.53M)(78.37M)(107.96M)--[{"date":"2020-12-31","value":-2853200000,"profit":false},{"date":"2021-12-31","value":-7836600000,"profit":false},{"date":"2022-12-31","value":-10795600000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(28.17M)(83.75M)(108.43M)(181.42M)(135.12M)[{"date":"2020-12-31","value":-2817400000,"profit":false},{"date":"2021-12-31","value":-8374600000,"profit":false},{"date":"2022-12-31","value":-10842600000,"profit":false},{"date":"2023-12-31","value":-18142300000,"profit":false},{"date":"2024-12-31","value":-13512200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(28.53M)(78.37M)(107.96M)(192.96M)(135.12M)[{"date":"2020-12-31","value":-2853200000,"profit":false},{"date":"2021-12-31","value":-7836600000,"profit":false},{"date":"2022-12-31","value":-10795600000,"profit":false},{"date":"2023-12-31","value":-19296200000,"profit":false},{"date":"2024-12-31","value":-13512200000,"profit":false}]
EPS (Diluted)(1.04)(4.45)(2.05)(3.30)(1.98)[{"date":"2020-12-31","value":-104,"profit":false},{"date":"2021-12-31","value":-445.47,"profit":false},{"date":"2022-12-31","value":-205,"profit":false},{"date":"2023-12-31","value":-330,"profit":false},{"date":"2024-12-31","value":-198,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VTYX
Cash Ratio 18.46
Current Ratio 19.57

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VTYX
ROA (LTM) -29.20%
ROE (LTM) -46.04%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VTYX
Debt Ratio Lower is generally better. Negative is bad. 0.09
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.91

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VTYX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.45
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Ventyx Biosciences Inc share price today?

Ventyx Biosciences Inc (VTYX) share price today is $1.59

Can Indians buy Ventyx Biosciences Inc shares?

Yes, Indians can buy shares of Ventyx Biosciences Inc (VTYX) on Vested. To buy Ventyx Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VTYX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ventyx Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Ventyx Biosciences Inc (VTYX) via the Vested app. You can start investing in Ventyx Biosciences Inc (VTYX) with a minimum investment of $1.

How to invest in Ventyx Biosciences Inc shares from India?

You can invest in shares of Ventyx Biosciences Inc (VTYX) via Vested in three simple steps:

  • Click on Sign Up or Invest in VTYX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ventyx Biosciences Inc shares
What is Ventyx Biosciences Inc 52-week high and low stock price?

The 52-week high price of Ventyx Biosciences Inc (VTYX) is $5.66. The 52-week low price of Ventyx Biosciences Inc (VTYX) is $0.78.

What is Ventyx Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ventyx Biosciences Inc (VTYX) is 0.45

What is the Market Cap of Ventyx Biosciences Inc?

The market capitalization of Ventyx Biosciences Inc (VTYX) is $85.39M

What is Ventyx Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Ventyx Biosciences Inc is VTYX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top